Scancell Holdings plc (LON:SCLP) Insider Buys £11,245.96 in Stock

Key Points

• Insider Martin Diggle purchased 102,236 shares of Scancell Holdings plc at an average cost of GBX 11 ($0.15) per share, totaling approximately £11,245.96 ($15,123.67).
• Prior to this purchase, Diggle also acquired 4,400,000 shares on August 1st for £440,000 ($591,715.98) at an average price of GBX 10 ($0.13).
• Scancell Holdings plc's stock has navigated between a one-year low of GBX 7.26 ($0.10) and a one-year high of GBX 19.75 ($0.27), with a current market cap of £114.45 million.

Scancell Holdings plc (LON:SCLP - Get Free Report) insider Martin Diggle bought 102,236 shares of the company's stock in a transaction dated Thursday, August 7th. The stock was purchased at an average price of GBX 11 ($0.15) per share, with a total value of £11,245.96 ($15,182.88).

Martin Diggle also recently made the following trade(s):

• On Friday, August 1st, Martin Diggle bought 4,400,000 shares of Scancell stock. The stock was purchased at an average price of GBX 10 ($0.14) per share, with a total value of £440,000 ($594,032.67).
• On Tuesday, May 20th, Martin Diggle purchased 44,944 shares of Scancell stock. The shares were bought at an average cost of GBX 9 ($0.12) per share, for a total transaction of £4,044.96 ($5,461.00).

Scancell Price Performance

Shares of Scancell stock traded down GBX 0.50 ($0.01) during midday trading on Tuesday, hitting GBX 10.50 ($0.14). 186,660 shares of the company traded hands, compared to its average volume of 973,678. The stock has a market cap of £108.75 million, a price-to-earnings ratio of -16.10 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The firm's fifty day moving average price is GBX 10.05 and its 200-day moving average price is GBX 9.49. Scancell Holdings plc has a 12 month low of GBX 7.26 ($0.10) and a 12 month high of GBX 19.75 ($0.27).

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.